ClinicalTrials.gg
CompletedNCT05624268Updated Aug 10, 2026

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

A Phase 3 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by COMPASS Pathways. Completed at 40 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by COMPASS Pathways · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Enrollment
2nd of 25
258 · median 30
Started
2023
with 2 others
Phase 3
3 of 25
none open now
Registered
10th of 25
by date
Lead sponsor
4 of 25
COMPASS Pathways

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 10th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Read the detailed description

This is a phase III, international, multi-centre, randomised, parallel group, fixed single-dose, double-blind, placebo-controlled study. The study population will include participants aged ≥18 years with TRD.

Overall, 255 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or placebo.

The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week Screening Period.

Part A will include a six-week follow-up from initial investigational product (IP) administration.

In this study, the primary aim is to assess the efficacy and safety of a single dose of COMP360 25 mg versus placebo for reducing symptom severity in TRD, when administered with psychological support. This will be assessed in a 6-week, single-dose, double-blind, placebo-controlled part of the study (Part A). Durability of efficacy and long-term safety, and the efficacy and safety of re-treatment will be assessed in a 20-week single-dose, double-blind re-treatment part (Part B), and a 26-week open-label treatment part (Part C).

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Aged ≥18 years at Screening
  2. Major depression without psychotic features (single or recurrent episode as informed by the , 5th edition [DSM-5])
  3. If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening
  4. MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression
  5. TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ.
  6. At Screening, agreement to discontinue all prohibited medications.

Key Exclusion Criteria:

Psychiatric Exclusion Criteria:

  1. Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)
  2. Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder, or any ongoing serious psychiatric comorbidity based on medical history and clinical judgement
  3. Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module
  4. Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)
  5. Psychiatric inpatient within the past 12 months prior to Screening
  6. Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode
  7. Transcranial magnetic stimulation within the past six months prior to Screening
  8. Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 30 days prior to Screening
  9. Exposure to COMP360 psilocybin therapy prior to Screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    25 mg COMP360 Psilocybin

    25 mg COMP360 Psilocybin

    Drug: Psilocybin

  • Placebo comparator
    Placebo

    Matched placebo

    Drug: Psilocybin

Interventions

  • COMP360 Psilocybin administered under supportive conditions

    Also known as: COMP360

06

What researchers measure

Primary outcomes

  1. COMP360 25 mg versus placebo for the change from baseline in MADRS total score

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity

    Time frame: Week 6

Secondary outcomes

  1. COMP360 25 mg versus placebo for the change from baseline in SDS total score

    Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.

    Time frame: Week 6

07

Study locations

40 sites
  • University of Arizona College of Medicine - Tuscon
    Tuscon, Arizona 85724, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Kadima Neuropsychiatry Institute
    La Jolla, California 92037, United States
  • University California San Diego
    La Jolla, California 92037, United States
  • California Center for Psychedelic Therapy
    Los Angeles, California 90004, United States
  • CalNeuro Research Group, Inc
    Los Angeles, California 90025, United States
  • Clarity Clinical Research, LLC
    Los Angeles, California 90064, United States
  • ATP Clinical Research, Inc.
    Orange, California 92868, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Lumos Clinical Research Center
    San Jose, California 95124, United States
  • Stanford University
    Stanford, California 94305, United States
  • ASCLEPES Research Centers
    Thousand Oaks, California 93012, United States
  • Comprehensive Psychiatric Care
    Norwich, Connecticut 06360, United States
  • Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare
    Orlando, Florida 32801, United States
  • APG Research, LLC
    Orlando, Florida 32803, United States
  • DMI Health Care Group, Inc
    Tampa, Florida 33782, United States
  • Meridien Research/Accel Research
    Tampa, Florida 33803, United States
  • Psych Atlanta
    Atlanta, Georgia 30060, United States
  • Emory University
    Atlanta, Georgia 30329-2209, United States
  • Uptown Research Institute, LLC
    Chicago, Illinois 60640, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21044, United States
  • CBH Health, LLC
    Gaithersburg, Maryland 20877, United States
  • Pharmasite Research, Inc
    Pikesville, Maryland 21208, United States
  • University of Massachusetts Medical School
    North Worcester, Massachusetts 01655, United States
  • University of Minnesota
    Minneapolis, Minnesota 55416, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Alivation Research, LLC.
    Lincoln, Nebraska 68526, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • New York State Psychiatric Institute
    New York, New York 10032, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • Insight Clinical Trials, LLC
    Beachwood, Ohio 44122, United States
  • Neuro-Behaviroral Clinical Research, Inc.
    North Canton, Ohio 44720, United States
  • Rivus Wellness & Research Institute
    Oklahoma City, Oklahoma 73112, United States
  • Global Medical Institutes, LLC, Scranton Medical Institute
    Moosic, Pennsylvania 18507, United States
  • UT Health Science Center at Houston (UTHSC-H)
    Houston, Texas 77030, United States
  • Cedar Clinical Research
    Draper, Utah 84020, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2025, 28 months.

Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 22, 2022
StartActual
Jan 24, 2023
Primary completionActual
May 28, 2025
CompletionActual
Apr 15, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05624268
Lead sponsor
COMPASS Pathways
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Jan 24, 2023
Primary completion
May 28, 2025
Completion
Apr 15, 2026
Last update
Aug 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion